Samantha Zullow1, Guruprasad Jambaulikar2, Ankur Rustgi2, Sandra Quezada2, Raymond K Cross2. 1. Department of Internal Medicine, Boston Medical Center, Boston University School of Medicine, 72 East Concord Street, Evans 124, Boston, MA, 02118, USA. Samantha.Zullow@bmc.org. 2. Division of Gastroenterology and Hepatology, Department of Medicine, University of Maryland, Baltimore, MD, USA.
Abstract
INTRODUCTION: Many patients with inflammatory bowel disease (IBD) are vitamin D deficient. The purpose of our study was to identify risk factors for vitamin D deficiency in IBD and to assess the impact of vitamin D repletion on disease activity and quality of life (QOL). METHODS: Patients with at least one 25-OH vitamin D level measured between 2004 and 2011 were included. Patients with a level <30 ng/ml at baseline were followed until the time of repletion. QOL and disease activity scores were measured at baseline and repletion. RESULTS: A total of 255 patients were identified. 33, 29, and 39% had a vitamin D level of ≥30, 20-29, and <20 ng/ml, respectively. When adjusting for disease type and duration, gender, smoking, and race, non-Caucasians had 5.3 (2.3-12.3) and UC patients had a 0.59 (0.33-1.03) odds of having a vitamin D <30 ng/ml. Women were 1.7 times more likely to have a 25-OH vitamin D level <20 ng/ml than men. 55 patients underwent repletion. In CD patients, the HBI and SIBDQ prior to repletion was 5.5 ± 4.9 and 44.3 ± 16.4, respectively; these improved to 3.6 ± 3.4 and 48.6 ± 14.2 after repletion (p = 0.0154 and p = 0.0684). CONCLUSIONS: In this tertiary care IBD cohort, the majority of patients have low vitamin D levels. Non-Caucasian race and female gender are associated with low vitamin D. UC was associated with lower risk of vitamin D insufficiency. In CD, vitamin D repletion is associated with decreased disease activity and increased QOL.
INTRODUCTION: Many patients with inflammatory bowel disease (IBD) are vitamin D deficient. The purpose of our study was to identify risk factors for vitamin Ddeficiency in IBD and to assess the impact of vitamin D repletion on disease activity and quality of life (QOL). METHODS:Patients with at least one 25-OH vitamin D level measured between 2004 and 2011 were included. Patients with a level <30 ng/ml at baseline were followed until the time of repletion. QOL and disease activity scores were measured at baseline and repletion. RESULTS: A total of 255 patients were identified. 33, 29, and 39% had a vitamin D level of ≥30, 20-29, and <20 ng/ml, respectively. When adjusting for disease type and duration, gender, smoking, and race, non-Caucasians had 5.3 (2.3-12.3) and UC patients had a 0.59 (0.33-1.03) odds of having a vitamin D <30 ng/ml. Women were 1.7 times more likely to have a 25-OH vitamin D level <20 ng/ml than men. 55 patients underwent repletion. In CDpatients, the HBI and SIBDQ prior to repletion was 5.5 ± 4.9 and 44.3 ± 16.4, respectively; these improved to 3.6 ± 3.4 and 48.6 ± 14.2 after repletion (p = 0.0154 and p = 0.0684). CONCLUSIONS: In this tertiary care IBD cohort, the majority of patients have low vitamin D levels. Non-Caucasian race and female gender are associated with low vitamin D. UC was associated with lower risk of vitamin Dinsufficiency. In CD, vitamin D repletion is associated with decreased disease activity and increased QOL.
Entities:
Keywords:
Disease activity; Inflammatory Bowel Disease; Vitamin D
Authors: Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren Journal: Can J Gastroenterol Date: 2005-09 Impact factor: 3.522
Authors: Toufic A Kabbani; Ioannis E Koutroubakis; Robert E Schoen; Claudia Ramos-Rivers; Nilesh Shah; Jason Swoger; Miguel Regueiro; Arthur Barrie; Marc Schwartz; Jana G Hashash; Leonard Baidoo; Michael A Dunn; David G Binion Journal: Am J Gastroenterol Date: 2016-03-08 Impact factor: 10.864
Authors: Pál Miheller; Györgyi Muzes; István Hritz; Gábor Lakatos; István Pregun; Péter László Lakatos; László Herszényi; Zsolt Tulassay Journal: Inflamm Bowel Dis Date: 2009-11 Impact factor: 5.325
Authors: S P Jørgensen; J Agnholt; H Glerup; S Lyhne; G E Villadsen; C L Hvas; L E Bartels; J Kelsen; L A Christensen; J F Dahlerup Journal: Aliment Pharmacol Ther Date: 2010-05-11 Impact factor: 8.171
Authors: Francisca Dias De Castro; Joana Magalhães; Pedro Boal Carvalho; Maria João Moreira; Paula Mota; José Cotter Journal: Arq Gastroenterol Date: 2015-12
Authors: Viktor Domislović; Darija Vranešić Bender; Ana Barišić; Marko Brinar; Dina Ljubas Kelečić; Cecilija Rotim; Martin Novosel; Marija Matašin; Željko Krznarić Journal: Acta Clin Croat Date: 2020-03 Impact factor: 0.780
Authors: Christine Elisabeth Janssen; Anna Maria Globig; Andrea Busse Grawitz; Dominik Bettinger; Peter Hasselblatt Journal: PLoS One Date: 2019-05-23 Impact factor: 3.240
Authors: Mia Bendix; Anders Dige; Søren Peter Jørgensen; Jens Frederik Dahlerup; Bo Martin Bibby; Bent Deleuran; Jørgen Agnholt Journal: Nutrients Date: 2020-11-30 Impact factor: 5.717